• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Lightlake files IND for intranasal naloxone, gets additional NIDA funding

Lightlake Therapeutics has announced that it filed an investigational new drug application for its intranasal naloxone therapy for the reversal of opioid overdose. The company also said that it has received additional funding from the National Institute on Drug Abuse (NIDA) for a new clinical trial of the product. Lightlake recently said that it had signed a manufacturing contract for its naloxone spray.

The new study will be the company’s second in collaboration with NIDA, which sponsored a 2-week Phase 1 pharmacokinetic study in 2013. According to Lightlake, the additional commitment from NIDA will allow the company to “evaluate its technology on a larger population.”

Lightlake CEO Roger Crystal commented, “We are extremely pleased that NIDA has continued its support of our opioid overdose reversal treatment. This support demonstrates NIDA’s commitment of having an FDA approved intranasal naloxone nasal spray available to the public.”

CFO Kevin Pollack added, “NIDA’s continued commitment to advancing our overdose reversal treatment reflects their confidence in the potential of our treatment. We believe that our treatment can make a huge difference in addressing the overdose epidemic and save a significant number of lives, and NIDA’s support plays a critical role in achieving our goals.”

Read the Lightlake press release.

Share

published on July 23, 2014

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews